Integrative Molecular Medicine
Online ISSN: 2056-6360
University College London
Cancer Treatment Centers of America
The Jikei University School of Medicine
Integrative Molecular Medicine is a peer-reviewed, online open access journal dedicated to a new research discipline at the interface between clinical research and basic biology. We aim to publish articles that broadly enlighten the biomedicine research community by providing an insight on breakthrough discoveries in basic and clinical medicinal research, thereby lending a strong impetus to this important and rapidly developing field and helping to forge new links between clinicians and molecular biologists. Integrative Molecular Medicine highlights ongoing integrative basic and clinical biomedicines covering fields of biology and medicine.As such the following qualities are essential in any article published by the journal: scientific credibility and rigour, and coherence and clarity in the writing. Contributions do not need to be novel as confirmatory and replication studies will be considered, however the article must present new findings, which could include the reporting of negative findings.
IMM provides a new platform for all researchers, scientists, scholars, students to publish their research work and update the latest research information.Integrative Molecular Medicine publishes research articles as full-length research papers and short reports. In addition, the journal publishes editorials and review articles in innovative formats that target a broad and non-specialized audience.
Journal will accept article from the following topics are integrative medical fields including biochemistry, molecular and cell biology, biotechnology, genetics, physiology, endocrinology, signal transduction, cell proliferation, differentiation and development, stem cells and regenerative medicine apoptosis, gene expression, pathology, metabolic disease, genomics, transcriptomics, proteomics, metabolomics of disease, systems medicine, brain disease, cardiovascular biology, diabetes, obesity, osteoporosis, nutrition, pharmacology, toxicology, cancer biology and oncology, epidemiology, genetic medicine, and other medicine-related topics.
IMM welcomes direct submissions of manuscripts from authors. You can submit your manuscript to: email@example.com
I graduated as an MD at Lviv State Medical University (Ukraine) in 1983 with a great passion to become a surgeon in oncology. Thinking that a PhD in experimental oncology would help to realize my dream, I obtained my doctorate at the Institute of Experimental Oncology, National Academy of Sciences of Ukraine in 1987. A fellowship from the International Agency for Research on Cancer (IARC) took me even further from clinical oncology and also from Ukraine. I arrived in London on the first wave of perestroika and began my post-doctoral training in Jim Woodgett's laboratory at the Ludwig Institute for Cancer Research (UCL Branch). Subsequently, I worked in Mike Waterfield's laboratory at the same Institute studying signal transduction via the PI3 kinase pathway. In 1996, I started my own group at the Ludwig Institute for Cancer Research, focusing on the regulation of growth via the S6 kinase pathway. Since 2003, I have been a Professor in the Department of Biochemistry at UCL – now renamed Structural and Molecular Biology, where I have an active research group working on signal transduction and cellular metabolism in health and disease. I have a strong research (113 papers in peer-reviewed journals, H-Index 52) and patent (10 world-wide patents) portfolio and run two drug discovery programs aimed at developing small molecule inhibitors, targeting ribosomal S6 kinase and Aurora A kinase.
Ricardo H. Alvarez
Dr. Alvarez, a native of Argentina, joined CTCA in October 2014 to lead the company’s global focus on cancer research. He is internationally known for his contribution to breast cancer multidisciplinary management, inflammatory breast cancer, and discovery and monitoring of minimal residual disease in solid tumors. As a medical oncologist, he has focused his clinical career the past two decades on treating patients with the most difficult cases of breast cancer. Prior to joining CTCA, Dr. Alvarez served for five years as an Assistant Professor in the University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology, Division of Cancer Medicine in Houston, Tx. He also served as Assistant Professor at The Morgan Welch Inflammatory Breast Cancer Research Program. His additional experience includes teaching at the Department of Pathology and the Department of Internal Medicine, Universidad Nacional de La Plata, Argentina. He served as Chief, Oncology Section, Hospital Ramon Carrillo - San Carlos de Bariloche, Rio Negro, Argentina, and Instructor, Oncology Consultants P.A., Houston, Tx. He was Secretary of Clinical Oncology Section, School of Oncology, Fundacion Jose Maria Mainetti, Centro Oncologico de Excelencia, Gonnet, Argentina; and Member, Centro Oncologico de Excelencia, Gonnet.
Dr. Alvarez received his medical degree from Universidad Nacional de La Plata - Facultad de Medicina, Argentina. He completed his residency in internal medicine and medical oncology at Centro Oncologico de Excelencia - Gonnet, Argentina. Following completion of his medical oncology training, he pursued additional training in Clinical Pathology to further study molecular diagnostic and serve as Instructor at the Pathology Department with Dr. Pedro Laguens at the Universidad Nacional de La Plata. He also participated in multiple research activities and attended multiple grand rounds with Professors Jose Maria Mainetti and Alberto Luchina, and with several others became leaders in Argentinean oncology. Following his training in Argentina, he moved to Houston to pursue a medical residency in internal medicine at The University of Texas at Houston, and completed a fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center, Houston, TX. He earned a master’s degree in cancer biology from the Graduate School of Biomedical Sciences at Houston. Dr. Alvarez has received numerous professional awards for his work in cancer research, including T-32 NIH CA009666 in 2006, Award of Excellence in Cancer Research by Texas Medical Society of Oncology in 2008, and the Susan Papizan Dolan Fellowship in Breast Cancer Research in 2008. He has participated in nearly $5 million in research grants and contracts with multiple clinical studies, including several Phase II Investigator Initiated Studies, since 2009 alone.
In 2014, he was Principal Investigator in a study related to monitoring minimal residual disease in locally advanced breast cancer and inflammatory breast cancer by detecting circulating tumor cells. The goal of this study, funded by Sister Institution Fund Network as part of the Global Academy Program Department at MD Anderson, is to identify molecular markers of breast cancer tumor recurrence. This clinical trial is currently active in the U.S., as well as in five academic Institutions across the world, including: INCan in Mexico, INEM in Peru, ClÍnica Alemana in Santiago de Chile, Barretos Hosptial in Brasil, and University of Oslo in Norway. Dr. Alvarez has authored more than 50 articles, abstracts and book chapters and is a frequent presenter at international oncology conferences. His professional memberships include: American Society of Clinical Oncology (ASCO,) American College of Physicians (ACP), American Society of Hematology (ASH), American Association of Cancer Research (AACR), and the Society of Clinical Research Associates (SOCRA). He was a founding member of Grupo de Estudio Tratamiento e Investigacion del Cancer del Sur (GETICS) in Argentina in 1996.
External Databases & Indexes
- German Cancer Research Center(dkfz)
- Google scholar
- German Journal Database (ZDB)
- Electronic Journals Library (EZB)
- ROAD directory
- SciCurve Open
- Scientific Indexing Services (SIS)\
All published articles are provided with DOI and are permanently archived at Open Access Text website in PDF and HTML formats.
IMM welcomes direct submissions of manuscripts from authors. You can submit your manuscript to:firstname.lastname@example.org; alternatively to:email@example.com
Integrative Molecular Medicine is an Open Access journal and we do not charge the end user when accessing a manuscript or any article. This allows the scientific community to view, download, distribution of an article in any medium, provided that the original work is properly cited, under the term of "Creative Commons Attribution License". In line with other open access journals we provide a flat fee submission structure on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway (the article processing charge). The process includes our maintenance, submission and peer review systems and international editing, publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article and associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically, legally and financially stable.
The publication charges for Integrative Molecular Medicine are GBP 1670
Frequently Asked Questions (FAQs)
Why are your charges set at these levels?
All articles published in OA Text are open access. Open Access publishing implies that all readers, anywhere in the world, are allowed unrestricted to full text of articles, immediately on publication in OA Text Journals. The Article Publication Charges pay for the editorial and production costs of the journal, for hosting the website, publishing articles online, preparing HTML , PDF and XML versions of the articles and submitting the articles in electronic citation database like CrossRef.
Our financial goals are to:
- Recover capitalization costs;
- Produce sufficient revenue to allow for a sustainable and scalable publishing program, under continuous development;
- Bend the publication-charge cost downward over time.
Who will pay the APC?
Corresponding author or Co-authors has to make the payment on acceptance of the article.
When should I pay?
Corresponding author or the paying institutions should arrange for the payment once they are notified regarding acceptance of the article. APC is exempted for cases in which a wavier agreement has been made in-prior to submission.
*We request an immediate attention towards the payment as the articles will not be published unless the charges have been paid.
How do I pay?
Authors or institutions can make payments by two modes as per their convenience.
- Wire/Bank transfer
- Card payment
Note: No taxes are included in this charge, taxes will be applicable as per the policies of the country of the payee. Additional transaction charges may be levied on the author.
Can I be eligible for wavier on APC?
The waiver request will be considered on a case-by-case basis, and will be provided accordingly.
*The Waiver requests must be made during the submission process and will not be accepted after processing of the manuscript.
Do I have to pay if my manuscript is rejected?
No, Article processing charges will not be applicable for articles rejected by the Editorial office.
Are reprints of my article included in the article processing charges (APCs)?
No, Article processing charges (APCs) do not include the charges for the reprints. Reprints facility is optional and should be order separately.
Ricardo H. Alvarez
Cancer Treatment Centers of America
Submission date: November 30, 2016
Publication date: January 31, 2017
Obstacles to the Medical Revolution
David W. Moskowitz
MD FACP, Founder and CEO, GenoMed, Inc. (www.genomed.com)
Submission date: June 30, 2016
Publication date: August 03, 2016
Description of the Special Issue: It's widely agreed that molecular medicine will revolutionize the practice of medicine. Few people realize that it's long overdue. Linus Pauling and colleagues published "Sickle Cell Anemia, a Molecular Disease," in the November 1949 issue of Science, but the treatment for sickle cell disease remains unsatisfactory over 65 years later.
What has been holding up the medical revolution? Papers are solicited on this general topic. They may address any of the following topics, or another that the author feels is equally important:
1. Problems solving polygenic diseases
2. Is there a better approach to oncology?
3. Drug discovery and development in the 21st century
4. Shifting the healthcare industry to prevention: economic and legal challenges
5. The role of public health authorities
6. The role of the media
7. The role of investors